单胺重摄取抑制剂抗抑郁作用评价策略和体系  

System for antidepressant evaluation of monoamine reuptake inhibitors

作　　者：薛瑞[1] 张有志[1] 李云峰[1] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国药理学通报》2011年第12期1636-1640,共5页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金面上资助项目(No30973516);国家自然科学基金青年科学基金项目(No81102423;81001653);国家科技重大专项新药创制专项资助项目(No2009ZX09103-025)

摘　　要：现有临床抗抑郁药物多以单胺为靶标设计,单胺重摄取抑制剂仍是抗抑郁新药研发的热点方向。新药研发周期长,投资高,风险大,如何快速准确完成药物筛选和临床前评价至关重要。该课题组采用体外高通量筛选和整体动物药效学验证相结合的评价模式,建立了单胺重摄取抑制剂评筛体系,该体系的建立将对单胺重摄取抑制剂的快速评价产生推动作用,也有助于挖掘新的研究思路。该文围绕抗抑郁药效学评价、作用靶标研究、单胺递质含量检测及神经元电活动研究对单胺重摄取抑制剂的评价策略和体系作一综述。Currently,commercially available antidepressants are synthetized targeting at monoamine system,and development of new monoamine reuptake inhibitors is still be of great interest for researchers.It is well known that new drug development needs great investment and long term studies,and is accompanied by high risk.So it is necessary and important to perform screening for potential monoamine inhibitors faster.Following long term effort and practice,our team established a series of strategies and an integrated system for antidepressant screening and evaluation of monoamine reuptake inhibitors,combining high throughput screening technology and in vivo animal tests together.Here,we review the strategies and system for antidepressants screening and evaluation,focusing on pharmacodynamic evaluation,target studies and monoamine determination.

关 键 词：单胺重摄取抑制剂 抗抑郁剂 药效评价 靶标研究 单胺递质 评价体系 

分 类 号：R-05[医药卫生] R971.43